无症状小腹主动脉瘤患者强化降脂的潜在获益与成本分析
本研究纳入583例30-54 mm无症状腹主动脉瘤患者,评估主要血管事件(MVE)和外周血管事件(PVE)发生率,并建模强化低密度脂蛋白胆固醇(LDL-C)降低方案的获益与成本。5年MVE和PVE发生率分别为38.1%和44.7%。若平均LDL-C降低1 mmol/L,理论可分别降低MVE绝对风险6.5%(95%CI 4.4-8.7;需治疗人数15)和PVE绝对风险5.3%(95%CI 1.4-7.5;需治疗人数19)。
要点
- 小无症状腹主动脉瘤患者5年主要血管事件风险达38.1%,外周血管事件风险达44.7%。
- 基线仅28.5%患者LDL-C<1.8 mmol/L,仅18.5%使用高强度他汀。
- 平均LDL-C降低1 mmol/L理论可降低MVE绝对风险6.5%、PVE绝对风险5.3%。
核心结论
- 小无症状腹主动脉瘤患者主要血管事件和外周血管事件风险高。
- 本研究为强化LDL-C降低方案的潜在获益和可允许费用提供了证据。
研究设计与样本
- 纳入583例腹主动脉瘤直径30-54 mm的无症状患者。
- 按招募年份将参与者分为约三等份,评估LDL-C控制和降脂药物处方。
- 前瞻性记录MVE和PVE,采用Kaplan-Meier分析计算事件发生率。
- 将既往随机对照试验报告的相对风险降低应用于本队列数据,建模平均LDL-C降低1 mmol/L的理论绝对风险降低和需治疗人数(NNT)。
- 采用成本效用分析估算具有成本效益的强化LDL-C降低方案的最大可允许费用。
主要发现
- 基线时仅28.5%的参与者LDL-C<1.8 mmol/L,仅18.5%处方高强度他汀(阿托伐他汀80 mg或瑞舒伐他汀40 mg)。
- 5年MVE发生率为38.1%,PVE发生率为44.7%。
- 若队列平均LDL-C降低1 mmol/L,理论可降低MVE绝对风险6.5%(95%CI 4.4-8.7;NNT 15)。
- 若队列平均LDL-C降低1 mmol/L,理论可降低PVE绝对风险5.3%(95%CI 1.4-7.5;NNT 19)。
临床怎么用
- 对小无症状腹主动脉瘤患者应评估LDL-C控制情况,基线达标率低提示存在治疗差距。
- 可考虑强化LDL-C降低策略以降低主要血管事件和外周血管事件风险。
- 强化降脂方案的成本效益需结合当地医疗支付意愿评估。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aims of this study were to assess the incidence of major vascular events (MVE) and peripheral vascular events (PVE) in people with a small asymptomatic abdominal aortic aneurysm (AAA) and model the theoretical benefits and costs of an intensified low density lipoprotein cholesterol (LDL-C) lowering programme. METHODS: A total of 583 participants with AAAs measuring 30 - 54 mm were included in this study. The control of LDL-C and prescription of lipid lowering drugs were assessed by dividing participants into approximately equal tertiles depending on their year of recruitment into the study. The occurrence of MVE (myocardial infarction, stroke, cardiovascular death, and coronary or non-coronary revascularisation) and PVE (non-coronary revascularisation, AAA repair, and major amputation) were recorded prospectively, and the incidence of these events was calculated using Kaplan-Meier analysis. The relative risk reduction reported for these events in a previous randomised control trial (RCT) was then applied to these figures to model the absolute risk reduction and numbers needed to treat (NTT) that could theoretically be achieved with a mean LDL-C lowering of 1 mmol/L. The maximum allowable expense for a cost effective intensive LDL-C lowering programme was estimated using a cost utility analysis. RESULTS: At entry, only 28.5% of participants had an LDL-C of < 1.8 mmol/L and only 18.5% were prescribed a high potency statin (atorvastatin 80 mg or rosuvastatin 40 mg). The five year incidences of MVE and PVE were 38.1% and 44.7%, respectively. It was estimated that if the mean LDL-C of the cohort had been reduced by 1 mmol/L, this could have reduced the absolute risk of MVE and PVE by 6.5% (95% CI 4.4 - 8.7; NNT 15) and 5.3% (95% CI 1.4 - 7.5; NNT 19), respectively. It was estimated that the maximum allowable expense for a cost effective LDL-C lowering programme would be between $1 239 AUD (€768) and $1 582 AUD (€981) per person per annum over a five year period. CONCLUSION: People with a small asymptomatic AAA are at high risk of MVE and PVE. This study provides evidence of the possible benefits and allowable expense for a cost effective intensive LDL-C lowering programme in this population.
引用
- Nastasi DR, Norman R, Moxon JV, et al. The Potential Benefits and Costs of an Intensified Approach to Low Density Lipoprotein Cholesterol Lowering in People with Abdominal Aortic Aneurysm. Eur J Vasc Endovasc Surg. 2021. PMID: 34507892. doi:10.1016/j.ejvs.2021.06.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。